Glenmark Pharma share price added 2 percent after the company entered into an exclusive licensing agreement with Menarini.
Glenmark Pharmaceuticals announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive

licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal spray Ryaltris across 33

countries in Europe, including the Balkan region, the company said in an exchange filing.

News Source:- Moneycontrol